If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.99B ...

A GSK logo is seen on the side of an office building in Poznan, Poland.

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

Vaccine makers face a demand cliff as coronavirus vaccines wane, but these stocks are more than meets the eye.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make ...